Mandate

Vinge advises Aleris in connection with the acquisition of Art Clinic AB

May 03, 2022 M&A

Vinge advises Aleris Sjukvård AB in connection with the acquisition of Art Clinic AB. Art Clinic AB operates four specialized clinics with five sub-practices in six regions in Sweden.

Aleris is one of Scandinavia’s leading healthcare provider with two million patient appointments per year and operates specialized care at over 130 locations in Sweden, Norway and Denmark. Aleris strengthens through the transaction its specialized healthcare within orthopedics, back surgery as well as aesthetic and reconstructive plastic surgery in Sweden.

Closing of the transaction is subject to applicable competition law approvals and other customary closing conditions.

Vinge’s team consisted of Christina Kokko, Samra Baytar, Olivia Belding and Elias Bohlin (M&A), Johan Wahlbom (Competition), Christoffer Nordin, Sam Fakhraie Ardekani and Max Hetta (Agreements), Emil Lindwall (Employment), Nour Makie (Banking and Finance), Karolina Fuhrman (IT/GDPR), Frida Ställborn (Real Estate) and Jessica Henning (VDR specialist).

Related

Vinge advises Röko AB (publ) in connection with the establishment of its MTN programme

Vinge has advised Röko AB (publ) ("Röko") on the establishment of a medium-term note programme (the "MTN Programme") with a framework amount of SEK 5 billion.
November 13, 2026

Vinge advises Telavox on the sale of its Nordic customer base to Telia

Vinge has advised Telavox AB (“Telavox”) on the sale of Telavox’s Nordic customer base for business services to Telia Company AB (“Telia”). The customer base comprises approximately 24,000 business customers and 325,000 end users in Sweden, Denmark, Finland, and Norway. The purchase price amounts to SEK 3.8 billion plus a potential additional earn-out.
November 13, 2026

Vinge has advised Course Corrected VC on the establishment of Course Corrected VC Fund II

Vinge has advised Course Corrected VC on the establishment and structuring of their second fund, Course Corrected VC Fund II (the “Fund”).
November 12, 2026